Your browser is no longer supported. Please, upgrade your browser.
AMRN Amarin Corporation plc daily Stock Chart
AMRN [NASD]
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.05 Insider Own0.90% Shs Outstand361.14M Perf Week-2.89%
Market Cap2.56B Forward P/E12.40 EPS next Y0.54 Insider Trans0.00% Shs Float347.03M Perf Month-4.68%
Income-18.80M PEG- EPS next Q-0.07 Inst Own45.80% Short Float9.31% Perf Quarter11.07%
Sales511.50M P/S5.01 EPS this Y83.10% Inst Trans-0.54% Short Ratio3.76 Perf Half Y-66.38%
Book/sh1.56 P/B4.31 EPS next Y550.00% ROA-2.40% Target Price- Perf Year-69.43%
Cash/sh1.42 P/C4.72 EPS next 5Y42.30% ROE-4.10% 52W Range3.95 - 26.12 Perf YTD-68.66%
Dividend- P/FCF- EPS past 5Y27.30% ROI-3.80% 52W High-74.85% Beta2.74
Dividend %- Quick Ratio2.30 Sales past 5Y51.30% Gross Margin77.80% 52W Low66.33% ATR0.33
Employees965 Current Ratio2.60 Sales Q/Q111.50% Oper. Margin-5.00% RSI (14)40.54 Volatility3.07% 5.20%
OptionableYes Debt/Eq0.07 EPS Q/Q23.40% Profit Margin-3.70% Rel Volume0.67 Prev Close6.72
ShortableYes LT Debt/Eq0.00 EarningsApr 30 BMO Payout- Avg Volume8.59M Price6.57
Recom2.20 SMA20-4.06% SMA50-7.39% SMA200-52.82% Volume907,088 Change-2.23%
May-05-20Initiated Northland Capital Outperform $15
Mar-31-20Upgrade Oppenheimer Underperform → Perform
Mar-31-20Downgrade Jefferies Buy → Hold $30 → $4
Mar-31-20Downgrade Goldman Buy → Neutral
Mar-13-20Upgrade Goldman Neutral → Buy $28
Mar-02-20Initiated Cowen Outperform $23
Feb-18-20Upgrade Citigroup Neutral → Buy $27 → $24
Jan-06-20Initiated JP Morgan Neutral $22
Dec-16-19Downgrade Stifel Buy → Hold
Nov-20-19Initiated Oppenheimer Underperform $7
Nov-18-19Downgrade Citigroup Buy → Neutral
Nov-15-19Reiterated SVB Leerink Outperform $26 → $29
Oct-31-19Initiated Aegis Capital Buy $23
Oct-15-19Initiated Goldman Neutral $17
Aug-14-19Initiated SVB Leerink Outperform $26
Jul-09-19Reiterated Jefferies Buy $30
Jun-17-19Initiated ROTH Capital Buy $31
Mar-22-19Initiated Stifel Buy $27
Nov-14-18Upgrade Citigroup Neutral → Buy
Nov-02-18Downgrade Citigroup Buy → Neutral
Jul-08-20 02:14PM  
12:51PM  
Jul-03-20 12:42PM  
Jul-01-20 05:50PM  
Jun-30-20 08:39AM  
Jun-25-20 05:50PM  
Jun-23-20 05:34PM  
Jun-18-20 07:40PM  
05:50PM  
Jun-17-20 02:58PM  
11:52AM  
07:30AM  
03:02AM  
Jun-16-20 04:30PM  
Jun-15-20 07:00AM  
Jun-12-20 05:45PM  
Jun-10-20 12:20AM  
Jun-05-20 05:45PM  
Jun-04-20 07:15PM  
Jun-01-20 01:38PM  
07:00AM  
May-28-20 05:02PM  
May-22-20 01:23PM  
01:15PM  
09:07AM  
08:45AM  
08:22AM  
07:10AM  
May-21-20 04:07PM  
04:05PM  
May-19-20 05:07AM  
May-15-20 06:14PM  
May-14-20 02:50PM  
May-09-20 06:44AM  
May-06-20 11:26AM  
May-05-20 12:17PM  
May-04-20 06:43PM  
05:26AM  
May-01-20 10:51AM  
Apr-30-20 08:30PM  
09:08AM  
07:19AM  
Apr-29-20 11:54AM  
10:05AM  
Apr-28-20 11:53AM  
07:00AM  
Apr-24-20 06:45PM  
Apr-21-20 04:25PM  
Apr-16-20 08:33AM  
Apr-15-20 06:46AM  
Apr-14-20 07:59AM  
03:51AM  
Apr-13-20 06:17PM  
Apr-08-20 04:05PM  
Apr-06-20 11:44AM  
Apr-03-20 01:56PM  
Apr-02-20 01:30PM  
09:55AM  
Apr-01-20 12:15PM  
11:01AM  
Mar-31-20 06:19PM  
04:30PM  
12:00PM  
10:12AM  
08:50AM  
08:49AM  
08:26AM  
07:20AM  
07:00AM  
03:21AM  
Mar-30-20 06:37PM  
06:25PM  
11:45AM  
Mar-25-20 09:29AM  
Mar-22-20 11:01PM  
Mar-20-20 08:10AM  
Mar-18-20 08:51AM  
Mar-17-20 09:40AM  
Mar-16-20 08:00AM  
Mar-15-20 01:56PM  
Mar-06-20 06:50AM  
Mar-04-20 10:49AM  
Mar-01-20 08:38AM  
Feb-28-20 02:48PM  
10:07AM  
Feb-27-20 02:05PM  
Feb-26-20 04:46PM  
09:16AM  
Feb-25-20 04:05PM  
04:05PM  
08:28AM  
Feb-21-20 05:50PM  
Feb-20-20 09:25AM  
06:00AM  
Feb-19-20 04:15PM  
08:34AM  
Feb-18-20 08:48AM  
Feb-14-20 01:44PM  
11:41AM  
Feb-12-20 02:03PM  
Amarin Corporation plc, a pharmaceutical company, develops and commercializes therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing REDUCE-IT for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.